Cystoscopy

Urethral sounding: why some people find it pleasurable to insert objects into their urinary tube

Retrieved on: 
Wednesday, March 13, 2024

In case you’re wondering, the human urethra is a tube that carries urine from the bladder to outside the body.

Key Points: 
  • In case you’re wondering, the human urethra is a tube that carries urine from the bladder to outside the body.
  • Some people find it sexually pleasurable to insert objects – known as sounds, which are typically small glass or metal rods – or even fluid into the urethra.
  • Many objects have been used for sounding, however, and that’s one of the reasons the practice is so hazardous.
  • The urethra is a narrow outflow tube, usually less than 9mm wide, so squeezing objects into it isn’t usually recommended.
  • Megalouretha can lead to retention of objects in the urethra or bladder from clinical examinations such as cervical screening.

Risky business

  • It takes several turns to pass through the pelvic floor muscles, prostate and then, if inserted far enough, the bladder.
  • Urethral damage exposes the underlying connective tissues which can cause blood in the urine, as well as erectile dysfunction and even bladder rupture.
  • Trauma and damage may lead to further narrowing of the urethra in later life which may require medical intervention.

Sounds painful

  • But sounding can be highly sexually gratifying for some people.
  • The arousal and subsequent stimulation of the erectile tissue of the penis and clitoris usually occurs through one of two mechanisms: psychogenic (images or thoughts) or reflexogenic (touching).
  • The reflexogenic pathway is served by nerves which also innervate the lining of the urethra – the dorsal nerve(s) of the penis or clitoris.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Photocure ASA: Results for the fourth quarter of 2023

Retrieved on: 
Wednesday, February 21, 2024

Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.

Key Points: 
  • Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.
  • "Hexvix/Cysview revenue increased 20% year-over-year in the fourth quarter, and we delivered EBITDA of NOK 29.9 million.
  • Photocure reported total group revenues of NOK 142.5 million in the fourth quarter of 2023 (NOK 104.2 million), and EBITDA* of NOK 29.9 million (NOK -16.9 million), driven by a combination of unit volume growth, price increases and a benefit from foreign exchange.
  • At the end of the fourth quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 352, an increase of 17% or 51 towers since the fourth quarter of 2022.

Photocure ASA: Results for the fourth quarter of 2023

Retrieved on: 
Wednesday, February 21, 2024

Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.

Key Points: 
  • Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.
  • "Hexvix/Cysview revenue increased 20% year-over-year in the fourth quarter, and we delivered EBITDA of NOK 29.9 million.
  • Photocure reported total group revenues of NOK 142.5 million in the fourth quarter of 2023 (NOK 104.2 million), and EBITDA* of NOK 29.9 million (NOK -16.9 million), driven by a combination of unit volume growth, price increases and a benefit from foreign exchange.
  • At the end of the fourth quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 352, an increase of 17% or 51 towers since the fourth quarter of 2022.

Precision Optics Reports Second Quarter Fiscal Year 2024 Financial Results

Retrieved on: 
Wednesday, February 14, 2024

GARDNER, Mass., Feb. 14, 2024 /PRNewswire/ -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its second quarter fiscal year 2024 for the period ended December 31, 2023.

Key Points: 
  • GARDNER, Mass., Feb. 14, 2024 /PRNewswire/ -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its second quarter fiscal year 2024 for the period ended December 31, 2023.
  • Q2 2024 Financial Highlights (3 Months Ended December 31, 2023):
    Revenue decreased 18% to $4.8 million, compared to $5.9 million in the same quarter of the previous fiscal year, but up 12% from the most recent sequential quarter.
  • Engineering revenue increased 33% to $2.3 million compared to $1.7 million in the same quarter of the previous fiscal year, and up 19% from the most recent sequential quarter.
  • The following table summarizes the second quarter and fiscal year to date (unaudited) results for the periods ended December 31, 2023, and 2022:

Agilis Robotics Unveils Groundbreaking Advancements in Endoluminal Surgery

Retrieved on: 
Monday, February 5, 2024

HONG KONG, Feb. 2, 2024 /PRNewswire/ -- Agilis Robotics, a leading innovator in surgical robotics, is spearheading a paradigm shift in the field of "incisionless" endoluminal surgery.

Key Points: 
  • HONG KONG, Feb. 2, 2024 /PRNewswire/ -- Agilis Robotics, a leading innovator in surgical robotics, is spearheading a paradigm shift in the field of "incisionless" endoluminal surgery.
  • The robotic instruments offer unprecedented possibilities across endoluminal surgery, spanning the upper and lower gastrointestinal (GI) tract, urinary tract, throat, and gynaecology.
  • Agilis Robotics is a spin-off from The University of Hong Kong and has secured more than HKD 90 million in funding from private investors.
  • Furthermore, Agilis Robotics understands the importance of cost-effectiveness, marketability, and market potential, ensuring a successful venture for investors and hospitals.

AUA, SUO Release Amendment to Non-Muscle Invasive Bladder Cancer Guideline

Retrieved on: 
Wednesday, January 24, 2024

BALTIMORE, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline amendment for the diagnosis and treatment of non-muscle invasive bladder cancer.

Key Points: 
  • BALTIMORE, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline amendment for the diagnosis and treatment of non-muscle invasive bladder cancer.
  • Bladder cancer continues to be a significant health issue in the United States, with non-muscle invasive bladder cancer (NMIBC) accounting for approximately 75% of the estimated 82,000 new cases diagnosed in 2023.
  • “One of the fastest growing spaces in Urologic Oncology is in the treatment of non-muscle invasive bladder cancer,” said Dr. Jeffrey M. Holzbeierlein, SUO president and chair for the guideline amendment.
  • Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment.

American Urological Association Announces 2024 Innovation Nexus Showcase Selections

Retrieved on: 
Wednesday, January 10, 2024

Baltimore, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce the ten companies chosen through a rigorous and highly competitive selection process for the second annual Innovation Nexus Showcase.

Key Points: 
  • Baltimore, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce the ten companies chosen through a rigorous and highly competitive selection process for the second annual Innovation Nexus Showcase.
  • Innovation Nexus is a long-term commitment by the AUA to sustain a urology incubator to advance discoveries with key stakeholders to benefit urologic patient care.
  • As part of the multi-faceted program, the AUA will host an annual Innovation Nexus Conference, with the second event being held on May 2 in San Antonio, TX, before the AUA Annual Meeting.
  • For more information on the Showcase and to register to attend the May 2 event, please visit: https://auanexus.org/

Vesica AI Selected as Winner of Inaugural Olympus Asia Pacific Innovation Program

Retrieved on: 
Thursday, December 7, 2023

SINGAPORE, Dec 7, 2023 - (JCN Newswire) - Vesica AI, a promising medical startup company, has been selected as the winner of the inaugural Olympus Asia Pacific Innovation Program (OAIP).

Key Points: 
  • SINGAPORE, Dec 7, 2023 - (JCN Newswire) - Vesica AI, a promising medical startup company, has been selected as the winner of the inaugural Olympus Asia Pacific Innovation Program (OAIP).
  • (From left) Olympus Corporation Asia Pacific CEO Marc Radatt, Vesica AI Co-founder, CMO, and CTO Atsushi Ikeda, Vesica AI CEO Albert Liu
    Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, partnered with MedTech Innovator Asia Pacific, the industry's largest healthcare accelerator, to launch and facilitate the OAIP which ran throughout 2023.
  • As the winning innovator, Vesica AI will receive grant funding of $75,000 as well as an exclusive mentorship program with key thought leaders from Olympus.
  • They presented strongly, and through this process, we are delighted to have selected Vesica AI as the inaugural winner of the Olympus Asia Pacific Innovation program.

Intelligent Scopes and Mayo Clinic Collaborate to Develop AI Diagnostic Solutions in Urology for Improved Patient Outcomes

Retrieved on: 
Thursday, December 21, 2023

LONDON and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, a subsidiary of Claritas HealthTech Ltd. is pleased to announce it has entered into a know-how agreement with Mayo Clinic to develop artificial intelligence (AI) solutions for surgical and endoscopic imaging in the field of urology.

Key Points: 
  • LONDON and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, a subsidiary of Claritas HealthTech Ltd. is pleased to announce it has entered into a know-how agreement with Mayo Clinic to develop artificial intelligence (AI) solutions for surgical and endoscopic imaging in the field of urology.
  • Combining the research capabilities and clinical expertise of Mayo Clinic, with the technology of Intelligent Scopes in image enhancement and expertise in development of precision AI diagnostic tools, this collaboration aims to deliver software tools that aid urologists in the detection, surgery, and post-treatment surveillance.
  • This digital healthcare collaboration intends to deliver reliable AI diagnostic solutions that can be used by urologists globally for accurate detection of bladder cancer and to minimize unnecessary interventions thereby improving patient outcomes.
  • Early and accurate detection has the potential to significantly improve the prognosis for patients and reduce costs to providers and payors.

Orion Research Foundation grants EUR 1,112,000 for research in 2024

Retrieved on: 
Wednesday, November 15, 2023

Orion Research Foundation sr is distributing EUR 1,112,000 in research grants based on applications for 2024.

Key Points: 
  • Orion Research Foundation sr is distributing EUR 1,112,000 in research grants based on applications for 2024.
  • Orion Reaserch Foundation awards grants of max EUR 50,000 for 17 researchers for postdoctoral research and max EUR 6,000 for 95 young researchers for doctoral dissertation work.
  • One of the postdoctoral grants was distributed from Maritza and Reino Salonen’s Fund which is administered by Orion Research Foundation.
  • Orion Research Foundation sr is annually distributing its return on investment and donations from Orion Corporation as grants for young researchers for doctoral dissertation work and postdoctoral research.